Botanix Pharmaceuticals
A clinical-stage pharmaceutical company developing novel dermatological and antimicrobial treatments for common skin diseases, leveraging a proprietary drug delivery system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | AUD48.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 485 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (214 %) | - | - | (8706 %) | (2291 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (216 %) | - | - | (8893 %) | (2305 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 177 % | - | - | 5564 % | 301 % |
Source: Company filings or news article
Related Content
Botanix Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of novel treatments for skin diseases and infections. The company has a dual-platform approach, with a focus on both dermatology and antimicrobial solutions. Their dermatology pipeline includes candidates for conditions such as acne, atopic dermatitis, and plaque psoriasis, while their antimicrobial platform is aimed at developing new treatments for bacterial infections.
Botanix utilizes a proprietary drug delivery system called Permetrex, which is designed to enhance the delivery of active pharmaceutical ingredients directly to the skin. The company's business model is centered around conducting clinical research and advancing its product candidates through the various stages of development. As a publicly-listed company on the Australian Securities Exchange (ASX:BOT), Botanix is financed through a combination of equity funding and partnerships. The company operates in the global pharmaceutical market, with a presence in both Australia and the United States, and its target clients are patients suffering from common, yet underserved, skin conditions.
Keywords: dermatology, antimicrobial, clinical-stage, pharmaceutical, skin diseases, drug delivery, cannabinoid, acne, psoriasis, atopic dermatitis